Benmelstobart Plus Anlotinib Is Unlikely to Be Cost-Effective for Advanced Renal Cell Carcinoma: An Integrated Disease Burden and Cost-Effectiveness Analysis
Kidney cancer (KC) is an important public-health challenge in China. Although benmelstobart plus anlotinib (BEN + AL) improves survival compared with sunitinib (SUN) for advanced renal cell carcinoma, its economic value in the Chinese healthcare system remains uncertain. Epidemiological trends in KC...
Gardado en:
| Principais autores: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
SAGE Publishing
2026-04-01
|
| Series: | Inquiry: The Journal of Health Care Organization, Provision, and Financing |
| Acceso en liña: | https://doi.org/10.1177/00469580261440346 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|